Erasmus MC in Rotterdam began a DNA test Monday for premature babies in intensive care, NU.nl reports. The test identifies a ...
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on. Benchmark your ...
AIM ImmunoTech announced that CEO Tom Equels and Professor Casper H.J. van Eijck discussed the recently approved Phase 2 trial of AIM's Ampligen® (rintatolimod) combined with AstraZeneca's Imfinzi® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results